Incretin-based therapies (addressing 4 out of the 8 pathophysiological defects) with biguanide [metformin (MET)] or TZD (addressing insulin resistance in liver and skeletal muscle) seem to be a very good option. The gene discussed is GCG; the disease is Insulin resistance.